Details of the Drug
General Information of Drug (ID: DMLTNHY)
| Drug Name |
Acetic Acid Salicyloyl-Amino-Ester
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
O-Acetylsalicylhydroxamic Acid; ACETIC ACID SALICYLOYL-AMINO-ESTER; 199854-00-7; C9H9NO4; O-Acetyl Salicylhydroxamic Acid; N-(Acetyloxy)-2-hydroxybenzamide; SCL; N-Acetoxysalicylamide; AC1L9HR3; SCHEMBL4318044; CTK0A0021; PCFWLDHLJWUGSU-UHFFFAOYSA-N; MolPort-003-844-411; [(2-hydroxybenzoyl)amino] acetate; ZINC2046853; FCH850362; 1962AH; Benzamide, N-(acetyloxy)-2-hydroxy-; AKOS006293238; DB03667; AB22745; ACM199854007; (2-HYDROXYPHENYL)FORMAMIDO ACETATE; RT-014810; FT-0661357; 1846-EP2298783A1
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 195.17 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 1.4 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


